CRDF Cardiff Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRDF

Price (delayed)

$1.46

Market cap

$65.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.89

Enterprise value

$51.6M

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to ...

Highlights
Cardiff Oncology's debt has decreased by 13% YoY and by 4.7% QoQ
The gross profit has increased by 8% YoY
Cardiff Oncology's EPS has decreased by 22% YoY but it has increased by 4.3% QoQ
The net income has declined by 37% year-on-year
The quick ratio has contracted by 37% YoY and by 2.6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://cardiffoncology.com
Peers: OVID

Key stats

What are the main financial stats of CRDF
Market
Shares outstanding
44.68M
Market cap
$65.23M
Enterprise value
$51.6M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.61
Price to sales (P/S)
164.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
133.67
Earnings
Revenue
$386,000
EBIT
-$38.7M
EBITDA
-$38.47M
Free cash flow
-$34.83M
Per share
EPS
-$0.89
Free cash flow per share
-$0.8
Book value per share
$2.38
Revenue per share
$0.01
TBVPS
$2.66
Balance sheet
Total assets
$116.19M
Total liabilities
$9.85M
Debt
$2.72M
Equity
$106.34M
Working capital
$103.48M
Liquidity
Debt to equity
0.03
Current ratio
14.25
Quick ratio
13.58
Net debt/EBITDA
0.35
Margins
EBITDA margin
-9,965.8%
Gross margin
100%
Net margin
-10,026.9%
Operating margin
-10,337.3%
Efficiency
Return on assets
-30.4%
Return on equity
-33%
Return on invested capital
-37.3%
Return on capital employed
-35.7%
Return on sales
-10,026.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRDF stock price

How has the Cardiff Oncology stock price performed over time
Intraday
-3.95%
1 week
-15.61%
1 month
-10.98%
1 year
-42.29%
YTD
4.29%
QTD
4.29%

Financial performance

How have Cardiff Oncology's revenue and profit performed over time
Revenue
$386,000
Gross profit
$386,000
Operating income
-$39.9M
Net income
-$38.7M
Gross margin
100%
Net margin
-10,026.9%
CRDF's operating income is down by 38% year-on-year
The net income has declined by 37% year-on-year
The operating margin has declined by 29% year-on-year
Cardiff Oncology's net margin has decreased by 27% YoY

Growth

What is Cardiff Oncology's growth rate over time

Valuation

What is Cardiff Oncology stock price valuation
P/E
N/A
P/B
0.61
P/S
164.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
133.67
Cardiff Oncology's EPS has decreased by 22% YoY but it has increased by 4.3% QoQ
The stock's price to book (P/B) is 71% less than its 5-year quarterly average of 2.1 and 13% less than its last 4 quarters average of 0.7
The equity has declined by 24% year-on-year and by 6% since the previous quarter
The P/S is 49% less than the 5-year quarterly average of 323.4 and 25% less than the last 4 quarters average of 218.5
Cardiff Oncology's revenue has increased by 8% YoY

Efficiency

How efficient is Cardiff Oncology business performance
The company's return on invested capital has shrunk by 65% YoY and by 7% QoQ
Cardiff Oncology's return on equity has shrunk by 56% YoY and by 5% QoQ
CRDF's return on assets has dropped by 51% year-on-year and by 4.8% since the previous quarter
Cardiff Oncology's return on sales has decreased by 27% YoY

Dividends

What is CRDF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRDF.

Financial health

How did Cardiff Oncology financials performed over time
The quick ratio has contracted by 37% YoY and by 2.6% from the previous quarter
The company's current ratio fell by 36% YoY
Cardiff Oncology's debt is 97% lower than its equity
The debt to equity has soared by 50% YoY
The equity has declined by 24% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.